Halozyme Therapeutics, Inc. (HALO): Price and Financial Metrics


Halozyme Therapeutics, Inc. (HALO)

Today's Latest Price: $40.23 USD

0.91 (-2.21%)

Updated Nov 27 1:00pm

Add HALO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

HALO Stock Summary

  • HALO's current price/earnings ratio is 252.67, which is higher than 96.96% of US stocks with positive earnings.
  • With a price/sales ratio of 27.25, Halozyme Therapeutics Inc has a higher such ratio than 92.94% of stocks in our set.
  • With a year-over-year growth in debt of 516.54%, Halozyme Therapeutics Inc's debt growth rate surpasses 96.51% of about US stocks.
  • Stocks that are quantitatively similar to HALO, based on their financial statements, market capitalization, and price volatility, are AMPH, LSCC, AOSL, SLAB, and DBX.
  • Visit HALO's SEC page to see the company's official filings. To visit the company's web site, go to www.halozyme.com.

HALO Stock Price Chart Interactive Chart >

Price chart for HALO

HALO Price/Volume Stats

Current price $40.23 52-week high $41.55
Prev. close $41.14 52-week low $12.71
Day low $39.55 Volume 786,500
Day high $41.40 Avg. volume 1,604,557
50-day MA $31.62 Dividend yield N/A
200-day MA $25.72 Market Cap 5.44B

Halozyme Therapeutics, Inc. (HALO) Company Bio


Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company was founded in 1998 and is based in San Diego, California.


HALO Latest News Stream


Event/Time News Detail
Loading, please wait...

HALO Latest Social Stream


Loading social stream, please wait...

View Full HALO Social Stream

Latest HALO News From Around the Web

Below are the latest news stories about Halozyme Therapeutics Inc that investors may wish to consider to help them evaluate HALO as an investment opportunity.

Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze® In Non-Small Cell Lung Cancer

SAN DIEGO, Sept. 17, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator, Roche, presented a poster with data from Part 1 of its Phase 1b study (IMscin001) evaluating atezolizumab (Tecentriq®) for subcutaneous administration utilizing…

PR Newswire | September 17, 2020

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q2 2020 Results - Earnings Call Transcript

Halozyme Therapeutics, Inc. (HALO) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Al Kildani – Vice President-Investor Relations and Corporate Communications Helen Torley – President and Chief Executive Officer Elaine Sun – Chief Financial Officer Conference Call Participants Jim Birchenough – Wells Fargo Graig Suvannavejh...

SA Transcripts on Seeking Alpha | August 11, 2020

Halozyme Therapeutics EPS misses by $0.04, misses on revenue

Halozyme Therapeutics (HALO): Q2 GAAP EPS of $0.19 misses by $0.04.Revenue of $55.22M (+41.0% Y/Y) misses by $11.46M.Press Release...

Seeking Alpha | August 10, 2020

Halozyme To Host Second Quarter 2020 Financial Results Webcast And Conference Call

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2020 on Monday, August 10 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the second quarter ended June 30, 2020, following the close of trading.

Yahoo | July 29, 2020

Should You Take Comfort From Insider Transactions At Halozyme Therapeutics, Inc. (NASDAQ:HALO)?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

Yahoo | July 23, 2020

Read More 'HALO' Stories Here

HALO Price Returns

1-mo 43.68%
3-mo 38.75%
6-mo 65.76%
1-year 107.48%
3-year 115.48%
5-year 128.71%
YTD 126.90%
2019 21.19%
2018 -27.79%
2017 105.06%
2016 -42.99%
2015 79.59%

Continue Researching HALO

Want to see what other sources are saying about Halozyme Therapeutics Inc's financials and stock price? Try the links below:

Halozyme Therapeutics Inc (HALO) Stock Price | Nasdaq
Halozyme Therapeutics Inc (HALO) Stock Quote, History and News - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.1652 seconds.